Well, I spent a bit of time looking at the 10Q, tr
Post# of 36536
(Total Views: 363)
Posted On: 12/16/2019 9:51:04 PM
Well, I spent a bit of time looking at the 10Q, trying to look for positives, and here is what I found:
1) Finished Goods was built up by 130% or $367k. Hopefully this is largely Excellagen, and they are selling somewhat significant quantities now (relative to the paltry amount apparently sold in this Q).
Does anyone happen to know what the FG accounting method is? If it's a fairly std cost valuation, and it's primarily Excellagen as I hope, this could represent ~$15MM in potential revs. As Excellagen has a shelf life (can't remember, 3 months?), maybe this bodes well for the next Q. Anyone have any knowledge to add to this line of thinking?
2) Olaregen acquisition payments have ALL been officially postponed to 1/31/20. Maybe that date was chosen because they hope the S-1 $ will be available by then. Whatever the case we are not in arrears on payments for the asset that is most likely to produce short-term revs... which do matter, IMHO.
That's all I've got, although my expectations were pretty low for this Q. I have higher expectations for the next Q, however, with Excellagen ramping up, and possibly the S-1 $ hitting the bank (25% chance?).
What else to you all see?
1) Finished Goods was built up by 130% or $367k. Hopefully this is largely Excellagen, and they are selling somewhat significant quantities now (relative to the paltry amount apparently sold in this Q).
Does anyone happen to know what the FG accounting method is? If it's a fairly std cost valuation, and it's primarily Excellagen as I hope, this could represent ~$15MM in potential revs. As Excellagen has a shelf life (can't remember, 3 months?), maybe this bodes well for the next Q. Anyone have any knowledge to add to this line of thinking?
2) Olaregen acquisition payments have ALL been officially postponed to 1/31/20. Maybe that date was chosen because they hope the S-1 $ will be available by then. Whatever the case we are not in arrears on payments for the asset that is most likely to produce short-term revs... which do matter, IMHO.
That's all I've got, although my expectations were pretty low for this Q. I have higher expectations for the next Q, however, with Excellagen ramping up, and possibly the S-1 $ hitting the bank (25% chance?).
What else to you all see?
(1)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼